• 1H revenue of $44.1 million up $6.5m
• Gross margin 35.6% (1H FY25: 27.1%)
• 1H EBITDA of $6.9 million up $2.6m

Clover Corporation Limited (ASX:CLV), a leading provider of innovative nutritional ingredients, has reported a strong financial and operational performance for the six months ended 31 January 2026. Revenue increased to $44.1 million, up $6.5 million or 17% compared to 1H FY25, driven by continued recovery across Europe and ANZ markets with existing customer growth and the onboarding of new customers. Gross margin improved significantly, increasing by 850 basis points to 35.6%, up from 27.1% in 1H FY25, due to a favorable customer and product mix, as well as improved manufacturing performance. EBITDA increased by $2.6 million or 60% to $6.9 million. Net profit after tax (NPAT) was $4.2 million, up $1.8 million or 75% compared to 1H FY25. The company's cash position remained strong at $10.3 million as at 31 January 2026. Clover's strategic investment in the Melody Dairies facility in New Zealand continues to deliver improved plant utilization and efficiency, while the extraction of crude fish oil from tuna heads in Ecuador is contributing approximately 30% of tuna oil inputs. The company is also making progress with the registration of its Premneo product and the development of new products such as CholineXcel and diversified DHA and ARA offerings. The Board anticipates that the positive momentum from the first half will continue in the second half of FY26, based on current demand forecasts, and has provided revenue guidance for the full year of $92 to $96 million.

Revenue guidance for FY26 is $92 - 96 million.

The Board anticipates that the positive momentum from the first half of FY26 will carry forward, resulting in a stronger second half, based on current demand forecasts. This outlook assumes that geopolitical tensions will not worsen and supply chains will remain stable, ensuring both inbound material supplies and outbound shipments are not disrupted throughout the rest of the financial year.